tiprankstipranks
Advertisement
Advertisement
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
PremiumCompany AnnouncementsMesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
27d ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
29d ago
Mesoblast CEO Boosts Stake as Company Files New Equity Announcements
Premium
Company Announcements
Mesoblast CEO Boosts Stake as Company Files New Equity Announcements
1M ago
Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review
PremiumThe FlyMesoblast receives BLA filing number from FDA for rexlemestrocel-L review
2M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
Premium
Company Announcements
Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
3M ago
Mesoblast receives IND clearance from FDA for Ryoncil trial
PremiumThe FlyMesoblast receives IND clearance from FDA for Ryoncil trial
5M ago
Mesoblast reports $30.3M in Ryoncil sales in March quarter
Premium
The Fly
Mesoblast reports $30.3M in Ryoncil sales in March quarter
5M ago
Mesoblast reports March quarter Ryoncil sales of $30.3M
Premium
The Fly
Mesoblast reports March quarter Ryoncil sales of $30.3M
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100